Bionano Genomics(BNGO)
Search documents
Bionano to Report Fourth Quarter and Year End 2023 Financial Results and Host a Conference Call and Webcast on March 5, 2024
GlobeNewsWire· 2024-02-28 13:01
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Tuesday, March 5, 2024, at 4:30 p.m. Eastern Time to report financial results for the fourth quarter and year end 2023 and to highlight recent corporate progress. Conference Call & Webcast Details Date:Tuesday, March 5th, 2024Time:4:30 p.m. ETParticipant Call Link:Registration – Click HereWebcast Link:https://edge.media-server.com/mmc/p/afaym86g/ Particip ...
Bionano Announces Amendment to Debt Financing Arrangement to Extend Cash Runway
Newsfilter· 2024-02-28 13:00
SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. ("Bionano") (NASDAQ:BNGO) today announced that is has amended the convertible debt financing the company entered into in October 2023 pursuant to which the company agreed to issue and sell to a certain accredited investor (the "Buyer") (i) in a registered offering by the company (a) $45.0 million aggregate principal amount of senior secured convertible notes due 2025 initially convertible by the Buyer into approximately 15.7 million shares ...
7 Penny Stocks to Buy on the Dip: February 2024
InvestorPlace· 2024-02-07 18:10
Now might be a good time to consider scooping up shares of penny stocks to buy on the dip. However, caution is essential, as penny stocks can be volatile and speculative. So to help reduce the risk to investors, I’ve chosen companies that seem to be on the safer side in terms of their fundamentals.So here are seven penny stocks to buy on the dip for February.BioNano Genomics (BNGO)Source: Dennis Diatel / Shutterstock.comBioNano Genomics (NASDAQ:BNGO) is a biotech stock that specializes in the analysis of ge ...
Bionano's Symposium 2024 Featured Presentations from its Global User Community Highlighting OGM as a Powerful Alternative to Classical Cytogenetics and Strong Complement to NGS
Newsfilter· 2024-01-30 13:00
Over 2,100 registrants with attendees from 92 countriesAverage daily attendance of 574 32 oral presentations delivered across four consecutive days69 scientific posters featuring optical genome mapping (OGM) on view in the online exhibit hallContent covered wide a range of research applications for OGM including hematologic malignancies, cell and gene therapy, and constitutional genetic diseasesOn-demand presentations from Symposium available for remainder of 2024 SAN DIEGO, Jan. 30, 2024 (GLOBE NEWSWIRE) - ...
Bionano Announces Publication of a Study that Applied OGM to Discovery of Structural Variants Driving Drug Resistance and Sensitivity in Cancer
Newsfilter· 2024-01-25 13:00
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (NASDAQ:BNGO) today announced a peer-reviewed publication in Cancers from a team of cancer researchers primarily at the NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute and Scripps MD Anderson in La Jolla, California. The publication describes what could be the first study to use optical genome mapping (OGM) for the discovery of structural variants (SVs) that drive drug resistance and sensitivity in cancer. ...
Bionano Announces Publication of Interim Readout from Second Phase of Clinical Trial Analyzing Optical Genome Mapping as Standard of Care (SOC) for Prenatal Testing
Newsfilter· 2024-01-24 13:00
Pre-print publication from Levy, et al. describes the second phase of a multisite evaluation and validation of optical genome mapping (OGM) that is designed to measure the workflow's accuracy and clinical utility compared to classical cytogenetic methodsOGM data from 342 unique cases (419 datapoints) were analyzed and reported in the pre-print, including 123 samples from phase 1 of the study, which was reported in a pre-print publication in December 2022Phase 2 results show that OGM demonstrates comparable ...
Bionano Announces Full Commercial Release of the Stratys™ System for High Throughput Optical Genome Mapping
Newsfilter· 2024-01-23 13:00
Bionano has completed the early access program for the Stratys™ system and is now making it available in a full commercial releaseThe Stratys instrument can enable up to a four-fold increase in raw data generation rate compared to the Saphyr® instrument and can process up to 12 single access chips, accessible as they complete runs, without the need to batch multiple samples on a consumableData analysis for the Stratys system is powered by Stratys™ Compute, a high-performance workstation developed in collabo ...
Bionano Announces the Final Speaker Lineup for 2024 Symposium with 33 OGM Presentations and Live Panel Discussions Across a Wide Range of Research Applications
Newsfilter· 2024-01-19 13:00
26 different customers representing North America, Asia and Europe33 oral presentations across four consecutive days69 scientific posters will be featured in a virtual exhibition hallTopics span the application of optical genome mapping (OGM) in research applications in cancer, cell and gene therapy, and genetic diseases SAN DIEGO, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc (NASDAQ:BNGO) today announced its 2024 Symposium lineup of 33 oral presentations delivered by 26 different customers world ...
Contrarian Kings: 3 Unloved Stocks That Could Be the Next Market Darlings
InvestorPlace· 2024-01-17 10:53
On Wall Street zeroes can become heroes relatively quickly. For example, in the past the Street hated Roku (NASDAQ:ROKU), Intel (NASDAQ:INTC), Shopify (NYSE:SHOP) and Pinterest (NYSE:PINS) and now they’re all among the most beloved names in the stock market. Often, positive macro trends can explain the transformation. For example, Roku and Pinterest got a big boost due to the acceleration of advertising spending. Obviously, investors can make a great deal of money by correctly predict which names will go fr ...
Bionano Announces Peer-Reviewed Publication from its Clinical Study Designed to Support OGM as Part of Standard of Care (SOC) in Genetic Disease Testing
Newsfilter· 2024-01-11 21:01
Peer-reviewed publication from Broeckel, et al. describes the second phase of a multisite evaluation of optical genome mapping (OGM) in 627 samples (597 unique samples and 30 replicates)Overall, for the entire study, OGM data have been collected from 1,000 samples, including 404 samples from phase 1 of the studyConcordance for pathogenic variants in all combined samples against standard of care (SOC) methods – 99.5% (995 out of 1,000 samples)When compared to the rate of finding pathogenic or likely pathogen ...